Meranda Parascandola - DSI InPharmatics

February 12, 2025

Published by Meranda Parascandola at February 12, 2025

The Cost of Goods Estimation: Balancing Efficiency and Budget in Drug Product Manufacturing

Cost estimation in drug product manufacturing is far from straightforward. Raw materials, labor, equipment, and quality and regulatory compliance all contribute to a complex web of expenses. Striking the right balance between operational efficiency and budget constraints poses a significant challenge for pharmaceutical companies. This balancing act becomes even more […]

March 3, 2025

Published by Meranda Parascandola at March 3, 2025

QP Certification VS QP Declaration: Is There a Difference?

Qualified person (QP) certification and declaration are distinct in their objectives within pharmaceutical and biotech industries. However, their similar names and overlapping functions can lead to confusion – particularly for those outside the EU/UK regulatory framework. Here’s a quick overview: Together, these processes are essential for maintaining EU regulatory compliance, […]

March 14, 2025

Published by Meranda Parascandola at March 14, 2025

A complete guide to CMC regulatory affairs services

Bringing a new drug to market requires more than just scientific innovation. It demands rigorous quality control, reliable manufacturing, and strict adherence to global regulatory standards. Agencies such as the FDA, EMA, MHRA, and PMDA impose Chemistry, Manufacturing, and Controls (CMC) requirements to ensure pharmaceutical products remain safe, effective, and […]

March 28, 2025

Published by Meranda Parascandola at March 28, 2025

Do You Need cGMP Quality Compliance Consulting Services?

Navigating the complexities of regulations in pharmaceuticals, biotechnology, or medical devices demands precision and expertise. Current Good Manufacturing Practices (cGMP) compliance isn’t optional—it drives business success and safeguards public trust. cGMP quality compliance consulting transforms these challenges into opportunities by crafting targeted strategies and delivering actionable guidance to ensure your […]

April 4, 2025

Published by Meranda Parascandola at April 4, 2025

FDA INTERACT Meetings: What You Need to Know

For early-stage drug developers, engaging with the FDA at the right time can be critical to success. One such opportunity is the INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs (INTERACT) meeting. This meeting provides early-stage guidance from the FDA’s Center for Biologics Evaluation and Research (CBER) and Center […]

April 4, 2025

Published by Meranda Parascandola at April 4, 2025

What is a Pre-NDA Meeting?

The path to FDA drug approval involves several critical milestones, one of the most important being the Pre-New Drug Application (Pre-NDA) meeting. This crucial step provides pharmaceutical companies with an opportunity to engage with the FDA before submitting a New Drug Application (NDA). Understanding the significance of a Pre-NDA meeting […]